Blue Horseshoe Stocks: Bottom-Bouncers & More


North Atlantic Drilling Ltd. NADL

We’ve got an array of potential bottom-bounce plays to go over this morning, the first of which is NADL. This stock has been getting beaten down incrementally since reaching a high of 4.80 in December. It’s been one selloff after another since then, culminating in a low of .65 during yesterday’s session.

We’re seeing a moderate gap-up this morning, and want to put NADL on our watchlist moving forward on the chance that a multi-day rebound is on the way.

__________

Catalyst BioSciences, Inc. CBIO

Next up on our bottom-bounce watchlist is CBIO, which is also gapping up off of a bottom in the premarket this morning with the help of a key press release, of which we’ll include a snippet below.

The stock recently made a massive run to the $18, so the potential for another major move is certainly present.

SOUTH SAN FRANCISCO, Calif., April 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc., (Nasdaq:CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a key milestone under its collaboration with ISU Abxis to advance the Factor IX program towards its first human clinical trial. Completion of the CB 2679d/ISU304 toxicology studies supported the recent Investigational New Drug (IND) approval by the Korean Ministry of Food and Drug Safety (MFDS) and triggered a milestone payment to Catalyst. (>>View Full PR)
__________

Sunshine Heart, Inc. SSH

We tagged SSH as a bottom play a week ago today on the 4th, and subsequently tracked it over a pretty nice run last week as it traded up from 1.67 and hit 2.25 (+35%). It pulled back to the low 1.70′s yesterday and appears to be gearing up for another possible move.

Just two months ago the stock was trading at more than $5/share, so we wanted to add a little reminder this morning that SSH could be line for an extended recovery that we’ll want to look out for in the day and weeks ahead.


Galectin Therapeutics, Inc. GALT

We were just mentioning yesterday morning the excellent move from GALT we had witnessed between first bringing it up in January and the present. The run, originating at a low of .935 had already reached just beyond the 200% level, and after a very nice intraday performance, our observed range was extended even further.

Trading up from a morning low to 2.75, the stock traded up 34% to reach 3.68. That pushed the overall percentage gain we’ve witnessed in GALT for 2017 to a highly respectable 294%


Extended Watchlist:
AMLH, SALE, GLBS, AKER, STAF